[First-line treatment of multiple myeloma]

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Therapeutic options for multiple myeloma have evolved significantly over the past two decades.
• High-dose chemotherapy with melphalan and autologous stem cell transplantation (ASCT) improved survival in younger, fit patients.
• Tandem transplantation approaches show promise for high-risk multiple myeloma patients.

Purpose of the Study:

• To review the changing landscape of therapeutic options for newly diagnosed multiple myeloma.
• To emphasize the importance of risk stratification in guiding first-line treatment decisions.
• To discuss the integration of novel agents and stem cell transplantation in managing multiple myeloma.

Main Methods:

• Review of recent clinical data and therapeutic advancements in multiple myeloma management.
• Analysis of the impact of novel agents (thalidomide, lenalidomide, bortezomib) and daratumumab.
• Evaluation of autologous and allogeneic stem cell transplantation strategies.

Main Results:

• Novel agents have expanded therapeutic perspectives for both transplant-eligible and ineligible patients.
• Bortezomib-based regimens are standard induction therapy in Germany, with lenalidomide combinations gaining traction.
• Daratumumab in combination therapy is a recent approval for newly diagnosed patients.

Conclusions:

• Risk stratification is essential for optimizing treatment strategies in newly diagnosed multiple myeloma.
• Stem cell transplantation, particularly ASCT, remains a cornerstone for eligible patients.
• Allogeneic stem cell transplantation is reserved for specific high-risk cases within clinical trials.